Energy homeostasis and cancer prevention: The AMP-activated protein kinase

Cancer Prevention Research

Volumn 2, Issue 4, 2009, Pages 301-309

  Fay, Judith R ^a   Steele, Vernon ^b   Crowell, James A ^c  

^a CCS Associates   (United States)

^b Division of Cancer Prevention   (United States)

^c NATIONAL CANCER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

A 769662; ANTIDIABETIC AGENT; DEGUELIN; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE KINASE; LEVACECARNINE; METFORMIN; PHENFORMIN; ROSIGLITAZONE; TROGLITAZONE; TUMOR SUPPRESSOR PROTEIN; UNCLASSIFIED DRUG; ADENYLATE KINASE;

AGING; BREAST CANCER; CALORIC INTAKE; CANCER INCIDENCE; CANCER PREVENTION; CARCINOGENESIS; CELL CYCLE ARREST; CELL CYCLE PROGRESSION; CELL ENERGY; CELL GROWTH; CELL SURVIVAL; CELL TRANSFORMATION; CHRONIC DISEASE; CLINICAL TRIAL; COLON CANCER; DIABETES MELLITUS; DRUG STRUCTURE; ENDOMETRIUM CANCER; ENERGY BALANCE; ESOPHAGUS CANCER; GASTROINTESTINAL SYMPTOM; GENE MUTATION; HEAD AND NECK CANCER; HOMEOSTASIS AND REGULATION; HUMAN; LACTIC ACIDOSIS; LUNG CANCER; MELANOMA; METABOLIC REGULATION; METABOLIC SYNDROME X; MOLECULAR MECHANICS; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; OBESITY; OVARY CANCER; PRIORITY JOURNAL; PROSTATE CANCER; PROTEIN SYNTHESIS; REVIEW; TUMOR GROWTH; TUMOR PROMOTION; ANIMAL; ENERGY METABOLISM; ENZYMOLOGY; METABOLISM; NEOPLASM; PHYSIOLOGY;

ADENYLATE KINASE; AMP-ACTIVATED PROTEIN KINASES; ANIMALS; ENERGY METABOLISM; HUMANS; NEOPLASMS;

EID: 67549131188     PISSN: 19406207     EISSN: None     Source Type: Journal    
DOI: 10.1158/1940-6207.CAPR-08-0166     Document Type: Review

References (84)

1. Crowell JA, Steele VE, Fay JR. Targeting the AKT protein kinase for cancer chemoprevention. Mol Cancer Ther 2007;6:2139-2148 (Pubitemid 47294742)
2. Kopelovich L, Fay JR, Sigman CC, Crowell JA. The mammalian target of rapamycin pathway as a potential target for cancer chemoprevention. Cancer Epidemiol Biomarkers Prev 2007;16:1330-1340 (Pubitemid 47076862)
3. Fay JR, Crowell JA, Kopelovich L. Targeting epigenetic regulatory mechanisms in cancer chemoprevention. Expert Opin Ther Targets 2005;9:315-328 (Pubitemid 40613871)
4. Hardie DG. AMP-activated/SNF1 protein kinases: conserved guardians of cellular energy. Nat Rev Mol Cell Biol 2007;8:774-785
5. Hardie DG. AMP-activated protein kinase as a drug target. Annu Rev Pharmacol Toxicol 2007;47:185-210. (Pubitemid 46272128)
6. Misra P. AMP activated protein kinase: a next generation target for total metabolic control. Expert Opin Ther Targets 2008;12:91-100. (Pubitemid 351247165)
7. Hardie DG, Hawley SA, Scott JW. AMP-activated protein kinase - development of the energy sensor concept. J Physiol 2006;574:7-15. (Pubitemid 43905792)
8. Towler MC, Hardie DG. AMP-activated protein kinase in metabolic control and insulin signaling. Circ Res 2007;100:328-341
9. Hardie DG. Role of AMP-activated protein kinase in the metabolic syndrome and in heart disease. FEBS Lett 2008;582:81-89 (Pubitemid 350297243)
10. Luo Z, Saha AK, Xiang X, Ruderman NB. AMPK, the metabolic syndrome and cancer. Trends Pharmacol Sci 2005;26:69-76.
11. Narkar VA, Downes M, Yu RT, et al. AMPK and PPARδ agonists are exercise mimetics. Cell 2008;134:405-415
12. Jiang W, Zhu Z, Thompson HJ. Dietary energy restriction modulates the activity of AMP-activated protein kinase, Akt, and mammalian target of rapamycin in mammary carcinomas, mammary gland, and liver. Cancer Res 2008;68:5492-5499
13. Sanchez-Cespedes M. A role for LKB1 gene in human cancer beyond the Peutz-Jeghers syndrome. Oncogene 2007;26:7825-7832 (Pubitemid 350261789)
14. Fenton H, Carlile B, Montgomery EA, et al. LKB1 protein expression in human breast cancer. Appl Immunohistochem Mol Morphol 2006;14:146-153 (Pubitemid 43941176)
15. Gurumurthy S, Hezel AF, Berger JH, Bosenberg MW, Bardeesy N. LKB1 deficiency sensitizes mice to carcinogen-induced tumorigenesis. Cancer Res 2008;68:55-63.
16. Swinnen JV, Beckers A, Brusselmans K, et al. Mimicry of a cellular low energy status blocks tumor cell anabolism and suppresses the malignant phenotype. Cancer Res 2005;65:2441-2448 (Pubitemid 40490156)
17. Rattan R, Giri S, Singh AK, Singh I. 5-Aminoimidazole-4-carboxamide-1- β-D-ribofuranoside inhibits cancer cell proliferation in vitro and in vivo via AMP-activated protein kinase. J Biol Chem 2005;280:39582-39593 (Pubitemid 41713917)
18. Lee JH, Koh H, Kim M, et al. Energy-dependent regulation of cell structure by AMP-activated protein kinase. Nature 2007;447:1017-1020 (Pubitemid 46975745)
19. Mirouse V, Swick LL, Kazgan N, St. Johnston D, Brenman JE. LKB1 and AMPK maintain epithelial cell polarity under energetic stress. J Cell Biol 2007;177:387-392 (Pubitemid 46718268)
20. Hahn-Windgassen A, Nogueira V, Chen C-C, Skeen JE, Sonenberg N, Hay N. Akt activates the mammalian target of rapamycin by regulating cellular ATP level and AMPK activity. J Biol Chem 2005;280:32081-32089 (Pubitemid 41361813)
21. Jin Q, Feng L, Behrens C, et al. Implication of AMP-activated protein kinase and Akt-regulated survivin in lung cancer chemopreventive activities of deguelin. Cancer Res 2007;67:11630-11639
22. Guertin DA, Sabatini DM. Defining the role of mTOR in cancer. Cancer Cell 2007;12:9-22.
23. Sancak Y, Thoreen CC, Peterson TR, et al. PRAS40 is an insulin-regulated inhibitor of the mTORC1 protein kinase. Mol Cell 2007;25:903-915 (Pubitemid 46436534)
24. Vander Haar E, Lee S-I, Bandhakavi S, Griffin TJ, Kim D-H. Insulin signalling to mTOR mediated by the Akt/PKB substrate PRAS40. Nat Cell Biol 2007;9:316-323 (Pubitemid 46344611)
25. Hardie DG. AMPK and Raptor: matching cell growth to energy supply. Mol Cell 2008;30:263-265
26. Gwinn DM, Shackelford DB, Egan DF, et al. AMPK phosphorylation of raptor mediates a metabolic checkpoint. Mol Cell 2008;30:214-226
27. Shaw RJ. Glucose metabolism and cancer. Curr Opin Cell Biol 2006;18:598-608.
28. Huang X, Wullschleger S, Shapiro N, et al. Important role of the LKB1-AMPK pathway in suppressing tumorigenesis in PTEN-deficient mice. Biochem J 2008;412:211-221 (Pubitemid 351758227)
29. Jones RG, Plas DR, Kubek S, et al. AMP-activated protein kinase induces a p53-dependent metabolic checkpoint. Mol Cell 2005;18:283-293 (Pubitemid 41350534)
30. Imamura K, Ogura T, Kishimoto A, Kaminishi M, Esumi H. Cell cycle regulation via p53 phosphorylation by a 5′-AMP activated protein kinase activator, 5-aminoimidazole-4-carboxamide-1-β-D-ribofuranoside, in a human hepatocellular carcinoma cell line. Biochem Biophys Res Commun 2001;287:562-567 (Pubitemid 32917636)
31. Xiang X, Saha AK, Wen R, Ruderman NB, Luo Z. AMP-activated protein kinase activators can inhibit the growth of prostate cancer cells by multiple mechanisms. Biochem Biophys Res Commun 2004;321:161-167 (Pubitemid 39055618)
32. Wang W, Yang X, Lopez de Silanes I, Carling D, Gorospe M. Increased AMP: ATP ratio and AMP-activated protein kinase activity during cellular senescence linked to reduced HuR function. J Biol Chem 2003;278:27016-27023 (Pubitemid 36876855)
33. Greer EL, Oskoui PR, Banko MR, et al. The energy sensor AMP-activated protein kinase directly regulates the mammalian FOXO3 transcription factor. J Biol Chem 2007;282:30107-30119
34. Greer EL, Dowlatshahi D, Banko MR, et al. An AMPK-FOXO pathway mediates longevity induced by a novel method of dietary restriction in C. elegans. Curr Biol 2007;17:1646-1656 (Pubitemid 47503807)
35. Katz MS. Therapy insight: Potential of statins for cancer chemoprevention and therapy. Nat Clin Pract Oncol 2005;2:82-89 (Pubitemid 40790141)
36. Farwell WR, Scranton RE, Lawler EV, et al. The association between statins and cancer incidence in a veterans population. J Natl Cancer Inst 2008;100:134-139
37. Bonovas S, Filioussi K, Flordellis CS, Sitaras NM. Statins and the risk of colorectal cancer: a meta-analysis of 18 studies involving more than 1.5 million patients. J Clin Oncol 2007;25:3462-3468 (Pubitemid 47310884)
38. Baur JA, Pearson KJ, Price NL, et al. Resveratrol improves health and survival of mice on a high-calorie diet. Nature 2006;444:337-342
39. Zakikhani M, Dowling R, Fantus IG, Sonenberg N, Pollak M. Metformin is an AMP kinase-dependent growth inhibitor for breast cancer cells. Cancer Res 2006;66:10269-10273 (Pubitemid 44799743)
40. Brusselmans K, De Schrijver E, Verhoeven G, Swinnen JV. RNA interference-mediated silencing of the acetyl-CoA-carboxylase-α gene induces growth inhibition and apoptosis of prostate cancer cells. Cancer Res 2005;65:6719-6725 (Pubitemid 41060709)
41. Alli PM, Pinn ML, Jaffee EM, McFadden JM, Kuhajda FP. Fatty acid synthase inhibitors are chemopreventive for mammary cancer in neu-N transgenic mice. Oncogene 2005;24:39-46.
42. An Z, Wang H, Song P, Zhang M, Geng X, Zou M-H. Nicotine-induced activation of AMP-activated protein kinase inhibits fatty acid synthase in 3T3L1 adipocytes: a role for oxidant stress. J Biol Chem 2007;282:26793-26801
43. Milgraum LZ, Witters LA, Pasternack GR, Kuhajda FP. Enzymes of the fatty acid synthesis pathway are highly expressed in in situ breast carcinoma. Clin Cancer Res 1997;3:2115-2120
44. Piyathilake CJ, Frost AR, Manne U, et al. The expression of fatty acid synthase (FASE) is an early event in the development and progression of squamous cell carcinoma of the lung. Hum Pathol 2000;31:1068-1073
45. Swinnen JV, Roskams T, Joniau S, et al. Overexpression of fatty acid synthase is an early and common event in the development of prostate cancer. Int J Cancer 2002;98:19-22. (Pubitemid 34113412)
46. Zhou W, Han WF, Landree LE, et al. Fatty acid synthase inhibition activates AMP-activated protein kinase in SKOV3 human ovarian cancer cells. Cancer Res 2007;67:2964-2971 (Pubitemid 46724832)
47. Buzzai M, Jones RG, Amaravadi RK, et al. Systemic treatment with the antidiabetic drug metformin selectively impairs p53-deficient tumor cell growth. Cancer Res 2007;67:6745-6752
48. Zou M-H, Kirkpatrick SS, Davis BJ, et al. Activation of the AMP-activated protein kinase by the anti-diabetic drug metformin in vivo. Role of mitochondrial reactive nitrogen species. J Biol Chem 2004;279:43940-43951
49. Shaw RJ, Lamia KA, Vasquez D, et al. The kinase LKB1 mediates glucose homeostasis in liver and therapeutic effects of metformin. Science 2005;310:1642-1646 (Pubitemid 41780780)
50. Phoenix KN, Vumbaca F, Claffey KP. Therapeutic metformin/AMPK activation promotes the angiogenic phenotype in the ERα negative MDA-MB-435 breast cancer model. Breast Cancer Res Treat 2009;113:101-111
51. Claffey KP. "Re: Metformin." Personal communication via email to author. 24 Mar 2008.
52. LeBrasseur NK, Kelly M, Tsao T-S, et al. Thiazolidinediones can rapidly activate AMP-activated protein kinase in mammalian tissues. Am J Physiol Endocrinol Metab 2006;291:E175-81. (Pubitemid 44035323)
53. He G, Sung YM, Digiovanni J, Fischer SM. Thiazolidinediones inhibit insulin-like growth factor-I-induced activation of p70S6 kinase and suppress insulin-like growth factor-I tumor-promoting activity. Cancer Res 2006;66:1873-1878 (Pubitemid 43259975)
54. Han S, Roman J. Rosiglitazone suppresses human lung carcinoma cell growth through PPARγ-dependent and PPARγ-independent signal pathways. Mol Cancer Ther 2006;5:430-437
55. Memmott RM, Gills JJ, Hollingshead M, et al. Phosphatidylinositol ether lipid analogues induce AMP-activated protein kinase-dependent death in LKB1-mutant non small cell lung cancer cells. Cancer Res 2008;68:580-588
56. Anisimov VN, Berstein LM, Egormin PA, et al. Effect of metformin on life span and on the development of spontaneous mammary tumors in HER-2/neu transgenic mice. Exp Gerontol 2005;40:685-693 (Pubitemid 41265819)
57. Schneider MB, Matsuzaki H, Haorah J, et al. Prevention of pancreatic cancer induction in hamsters by metformin. Gastroenterology 2001;120:1263-1270 (Pubitemid 32246678)
58. Evans JM, Donnelly LA, Emslie-Smith AM, Alessi DR, Morris AD. Metformin and reduced risk of cancer in diabetic patients. BMJ 2005;330:1304-1305
59. Bowker SL, Majumdar SR, Veugelers P, Johnson JA. Increased cancer-related mortality for patients with type 2 diabetes who use sulfonylureas or insulin. Diabetes Care 2006;29:254-258 (Pubitemid 44106500)
60. Sanders MJ, Ali ZS, Hegarty BD, Heath R, Snowden MA, Carling D. Defining the mechanism of activation of AMP-activated protein kinase by the small molecule A-769662, a member of the thienopyridone family. J Biol Chem 2007;282:32539-32548 (Pubitemid 350159309)
61. Goransson O, McBride A, Hawley SA, et al. Mechanism of action of A-769662, a valuable tool for activation of AMP-activated protein kinase. J Biol Chem 2007;282:32549-32560 (Pubitemid 350159310)
62. Chun KH, Kosmeder JW, Sun S, et al. Effects of deguelin on the phosphatidylinositol 3-kinase/Akt pathway and apoptosis in premalignant human bronchial epithelial cells. J Natl Cancer Inst 2003;95:291-302. (Pubitemid 36336479)
63. Lee H-Y, Oh S-H, Woo JK, et al. Chemopreventive effects of deguelin, a novel Akt inhibitor, on tobacco-induced lung tumorigenesis. J Natl Cancer Inst 2005;97:1695-1699
64. Hwang J-T, Ha J, Park I-J, et al. Apoptotic effect of EGCG in HT-29 colon cancer cells via AMPK signal pathway. Cancer Lett 2007;247:115-121 (Pubitemid 46001507)
65. Hwang J-T, Park I-J, Shin J-I, et al. Genistein, EGCG, and capsaicin inhibit adipocyte differentiation process via activating AMP-activated protein kinase. Biochem Biophys Res Commun 2005;338:694-699
66. Hwang J-T, Kim YM, Surh Y-J, et al. Selenium regulates cyclooxygenase-2 and extracellular signal-regulated kinase signaling pathways by activating AMP-activated protein kinase in colon cancer cells. Cancer Res 2006;66:10057-10063
67. Aggarwal BB, Shishodia S. Molecular targets of dietary agents for prevention and therapy of cancer. Biochem Pharmacol 2006;71:1397-1421
68. Hursting SD, Lavigne JA, Berrigan D, Perkins SN, Barrett JC. Calorie restriction, aging, and cancer prevention: mechanisms of action and applicability to humans. Annu Rev Med 2003;54:131-152 (Pubitemid 37386388)
69. Heilbronn LK, Ravussin E. Calorie restriction and aging: Review of the literature and implications for studies in humans. Am J Clin Nutr 2003;78:361-369 (Pubitemid 39663500)
70. Pollack MN. Insulin, insulin-like growth factors, insulin resistance, and neoplasia. Am J Clin Nutr 2007;86:s820-2.
71. Dhahbi JM, Mote PL, Fahy GM, Spindler SR. Identification of potential caloric restriction mimetics by microarray profiling. Physiol Genomics 2005;23:343-350
72. Fruman DA, Edinger AL. Cancer therapy: Staying current with AMPK. Biochem J 2008;412:e3-5.
73. Mutter GL, Lin M-C, Fitzgerald JT, et al. Altered PTEN expression as a diagnostic marker for the earliest endometrial precancers. J Natl Cancer Inst 2000;92:924-931
74. Brunet J, Vazquez-Martin A, Colomer R, GranaSuarez B, Martin-Castillo B, Menendez JA. BRCA1 and acetyl-CoA carboxylase: the metabolic syndrome of breast cancer. Mol Carcinog 2008;47:157-163 (Pubitemid 351231444)
75. Rosen EM, Fan S, Isaacs C. BRCA1 in hormonal carcinogenesis: Basic and clinical research. Endocr Relat Cancer 2005;12:533-548 (Pubitemid 41482992)
76. Drew BG, Kingwell BA. Acadesine, an adenosine-regulating agent with the potential for widespread indications. Expert Opin Pharmacother 2008;9:2137-2144
77. Xiao B, Heath R, Saiu P, et al. Structural basis for AMP binding to mammalian AMP-activated protein kinase. Nature 2007;449:496-500. (Pubitemid 47509548)
78. Amodeo GA, Rudolph MJ, Tong L. Crystal structure of the heterotrimer core of Saccharomyces cerevisiae AMPK homologue SNF1. Nature 2007;449:492-495 (Pubitemid 47509541)
79. Kato K, Ogura T, Kishimoto A, et al. Critical roles of AMP-activated protein kinase in constitutive tolerance of cancer cells to nutrient deprivation and tumor formation. Oncogene 2002;21:6082-6090
80. Laderoute KR, Amin K, Calaoagan JM, et al. 5′-AMP-activated protein kinase (AMPK) is induced by low-oxygen and glucose deprivation conditions found in solid-tumor microenvironments. Mol Cell Biol 2006:336-347 (Pubitemid 44036203)
81. Luo Y, Shoemaker AR, Liu X, et al. Potent and selective inhibitors of Akt kinases slow the progress of tumors in vivo. Mol Cancer Ther 2005;977-986 (Pubitemid 40909080)
82. Marshall S. Role of insulin, adipocyte hormones, and nutrient-sensing pathways in regulating fuel metabolism and energy homeostasis: a nutritional perspective of diabetes, obesity, and cancer. Si STKE 2006;re7.
83. Hannon TS, Rao G, Arslanian SA. Childhood obesity and type 2 diabetes mellitus. Pediatrics 2005;116:473-480
84. Kelloff GJ, Lippman SM, Dannenberg AJ, Sigman CC, et al. Progress in chemoprevention drug development: the promise of molecular biomarkers for prevention of Intraepithelial neoplasia and cancer - a plan to move forward. Clin Cancer Res 2006;12:3661-3697